



KNOW THE FLOW

**AI based Personalised Clinical Support Applications to Prevent,
Diagnose, and Treat Coagulation Disorders**

An independent Technology Spin-Off

Contents



Problem



Solution

Technology

Team & Partners

Clinicians lack actionable information to manage blood coagulation

- + Complications during and after surgery and for intensive care unit (ICU) patients



- + Coagulation is complex: multiple parameters & acute problem
- + Lab tests & guidelines provide **limited guidance**
- + **Complex data disseminated across several databases**

* pre-COVID-19 pandemic

Clinicians lack actionable information to manage blood coagulation

- + 16 recently interviewed Key Opinion Leaders (KOL) unanimously agree that:
 - + guidelines are poorly adopted due to complexity and fragmented information
 - + Inappropriate decisions result in excess morbidity, mortality and costs



Clinicians find it difficult to put all the data together from multiple sources simultaneously, and there is no doubt an integrated standalone system would improve patient care and contribute to improved patient outcomes, especially if it could give suggestions for management based on local and national guidelines. Even better would be a system that could learn and improve suggestions as time goes on by looking at what has and has not worked well and adapting appropriately”

Dr Andrew Klein, Chair of Dept of Anesthesia and Intensive Care
Royal Papworth NHS, Cambridge University, UK
Editor-in-Chief of Anesthesia



Coagulation in cardiac surgery is an example of biologic complexity baffling many who practice medicine. Artificial intelligence systems could provide an answer to assist the guidance of therapy for the prevention of and treatment of bleeding after heart surgery. I am excited to see a first foray into creating computer applications to tackle a problem that vexes many”

Bruce D Spiess, MD FAHA
Professor Of Anesthesiology, Associate Chair, Research
University Of Florida Health



Acting quickly and specifically upon coagulation complications, will reduce morbidity and mortality and improve patients outcome

Hemeo's Clinical Support Solutions will deliver simplicity, speed and predictability

- + Feeding with diagnostic, monitoring and coagulation data
 - + Data processed by algorithms => predictive simulations
 - + No extra input required, only simple customisable output
-
- + Maximum adoption with intuitive user interface built upon input from clinicians. 'red traffic light' drawing attention to specific parameters and recommending treatments in line with local guidelines

Hemeo's model has been verified against a retrospective database of 5,000 patients, to reflect highly diverse experimental and clinical coagulation conditions.

INPUT

Existing databases and information sources



Lab Information System




Anaesthesia-Patient Monitoring



EMR System

OUTPUT



"App" -- Intuitive Clinical Support tool

Example of Hemeo 1.0 -- other functionalities added in later generations

At least one parameter more than 10% out of guideline

At least one parameter less than 10% out of guideline

All parameters within guidelines

Hemeo's Applications are built in close collaboration with leading academic centres



Team & Partners highly committed with strong complementary expertise and a comprehensive ecosystem

TEAM



Remi Corlin
CEO

- 20+ years of experience with blood technologies in public companies and start-ups
- Successful track record growing businesses up to 100 staff and \$100M in Europe, US and Asia
- Investor in 3 small or early-stage ventures (incl. Hemeo)



René van den Ham
CTO

- PhD in cell and molecular biology
- 15+ years at Philips leading a team to invent the coagulation model
- Renowned data scientist with 20 publications



Dr Aamer Ahmed
CMO

- Cardio Anesthetist & Associate Professor
- 50+ publications & 700 citations
- Management of perioperative bleeding, thrombosis and haemostasis
- Elected UK representative for the ESA Council and UK ACTACC, Exec. Committee & member of EACTA Haemostasis and Thrombosis and Congenital Heart Disease Subcommittees

PARTNERS



Hemeo is part of the NLC ecosystem. NLC provides a broad range of shared support services and access to a highly specialised network across both the finance and clinical communities

PHILIPS

- Exclusive license agreement with Hemeo for a panel of patents and company secret
- Cloud platform Service agreement
- Product development support



Hôpital Cochin



Royal Papworth Hospital
NHS Foundation Trust




Amsterdam UMC

UFHealth
UNIVERSITY OF FLORIDA HEALTH

Pillars of Success

- >1B€ market potential within hospitals
- Demonstrated interest from clinical community
- Further market opportunities with:
 - Expanded clinical applications
 - Industry research



Exclusive License to 9 registered patents and company secrets based upon 15 years of research, to be augmented with new research

- Complementary experienced team of co-founders
- Technology partnership
- Venture building support
- Academic research collaboration



KNOW THE FLOW

Thank You

**For further information
please contact:**

Remi Corlin - [CEO](#)
r.corlin@hemeo.health
+44 7572 618 960



Paasheuvelweg 25-D5
1105 BP Amsterdam
The Netherlands
www.hemeo.health